RU2011148918A - Иммуноглобулин с двумя вариабельными доменами и его применение - Google Patents

Иммуноглобулин с двумя вариабельными доменами и его применение Download PDF

Info

Publication number
RU2011148918A
RU2011148918A RU2011148918/10A RU2011148918A RU2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918/10 A RU2011148918/10 A RU 2011148918/10A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A
Authority
RU
Russia
Prior art keywords
antigen
fragment
parent antibody
specified
test sample
Prior art date
Application number
RU2011148918/10A
Other languages
English (en)
Russian (ru)
Inventor
Тарик ГХАЮР
Сьюзан Э. БРОУФИ
Сушил Г. ДЕВАРЕ
Фрэнк К. ГРЕНЬЕ
Джеффри А. МУР
Цяоцяо ЖУАНЬ
Сергей И. ТЕТИН
Дженнифер М. СТЕЙНХАУС
Цзюньцзян ЛЮ
Салман АЛИ
Хина Н. САИД
Original Assignee
Эбботт Лэборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз filed Critical Эбботт Лэборетриз
Publication of RU2011148918A publication Critical patent/RU2011148918A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011148918/10A 2009-05-01 2010-04-30 Иммуноглобулин с двумя вариабельными доменами и его применение RU2011148918A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17480009P 2009-05-01 2009-05-01
US61/174,800 2009-05-01
PCT/US2010/033246 WO2010127294A2 (en) 2009-05-01 2010-04-30 Dual variable domain immunoglobulins and uses thereof

Publications (1)

Publication Number Publication Date
RU2011148918A true RU2011148918A (ru) 2013-06-10

Family

ID=43032808

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011148918/10A RU2011148918A (ru) 2009-05-01 2010-04-30 Иммуноглобулин с двумя вариабельными доменами и его применение

Country Status (14)

Country Link
US (1) US20110008766A1 (https=)
EP (1) EP2424566A4 (https=)
JP (1) JP2012525441A (https=)
KR (1) KR20140014382A (https=)
CN (1) CN102458459A (https=)
AU (1) AU2010242840B2 (https=)
BR (1) BRPI1012195A2 (https=)
CA (1) CA2760332A1 (https=)
IL (1) IL216048A0 (https=)
MX (1) MX2011011670A (https=)
RU (1) RU2011148918A (https=)
SG (1) SG175426A1 (https=)
TW (1) TW201116624A (https=)
WO (1) WO2010127294A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) * 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es) * 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
MX2011005953A (es) * 2008-12-04 2011-08-17 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5918275B2 (ja) 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
WO2013081612A1 (en) 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
GB201308271D0 (en) * 2013-05-08 2013-06-12 Nat Univ Ireland Semi-automated whole blood immuno potency assay
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JP2017501211A (ja) 2013-11-06 2017-01-12 アスチュート メディカル，インコーポレイテッド 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
ES2571441B1 (es) * 2014-11-24 2017-03-07 Instituto De Investigación Sanitaria - Fundación Jiménez Díaz Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
BR112020005737A2 (pt) * 2017-09-22 2020-11-17 F. Hoffmann-La Roche Ag anticorpo recombinante multivalente e uso do mesmo, kit e método para detectar um antígeno
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
EP4363454A4 (en) * 2021-06-30 2026-01-07 Univ Texas POLYPEPTIDES TARGETING CD70 POSITIVE CANCERS
CN114366853B (zh) * 2022-01-20 2023-04-14 华东理工大学 一种高诱骨活性牙种植体涂层及其制备方法
CN119708212A (zh) * 2023-09-21 2025-03-28 东莞市朋志生物科技有限公司 检测hiv p24的抗体对、试剂和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
JPWO2003027151A1 (ja) * 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
EP1860119B1 (en) * 2005-02-28 2011-08-03 Institute for Antibodies Co., Ltd. ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
EP2447281B1 (en) * 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20090027227A (ko) * 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
CA2914170C (en) * 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009003142A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland, Stanford Junior University Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
EP2185201A4 (en) * 2007-08-08 2011-11-30 Abbott Lab COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODIES
WO2009021754A2 (en) * 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
CA2702611A1 (en) * 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
MX2011003381A (es) * 2008-09-30 2011-04-21 Abbott Lab Metodo mejorado para despliegue de arn.
AR083672A1 (es) * 2010-11-02 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20130171059A1 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR089529A1 (es) * 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
BR112014016299A8 (pt) * 2011-12-30 2017-07-04 Abbvie Inc imunoglobulinas de domínio variável e usos das mesmas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl

Also Published As

Publication number Publication date
KR20140014382A (ko) 2014-02-06
CN102458459A (zh) 2012-05-16
AU2010242840A1 (en) 2011-12-15
IL216048A0 (en) 2012-01-31
WO2010127294A3 (en) 2011-01-20
EP2424566A2 (en) 2012-03-07
US20110008766A1 (en) 2011-01-13
AU2010242840B2 (en) 2014-04-17
MX2011011670A (es) 2011-11-18
SG175426A1 (en) 2011-12-29
EP2424566A4 (en) 2013-07-31
WO2010127294A2 (en) 2010-11-04
TW201116624A (en) 2011-05-16
CA2760332A1 (en) 2010-11-04
JP2012525441A (ja) 2012-10-22
BRPI1012195A2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
RU2011148918A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
JP7346300B2 (ja) 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
JP2022115986A5 (https=)
JP2021505844A (ja) Ｇｆａｐとｕｃｈ−ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
JP2021505843A (ja) グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
JP2020521951A (ja) 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
RU2011121818A (ru) Способ иммунологического анализа белка cxcl1 человека
JP2020516603A5 (https=)
US20240392034A1 (en) Clinical assessment of m-protein response in multiple myeloma
JP2023514952A (ja) 抗ｄ－ダイマー組換え抗体、その方法及び使用
US20230236178A1 (en) SPR-based dual-binding assay for the functional analysis of multispecific molecules
CA3180569A1 (en) Neutralizing antibody assay for therapeutic proteins
US11505614B2 (en) Antibodies binding to soluble BCMA
RU2016106708A (ru) Лекарственное средство, содержащее антитело к фосфолипазе d4
Bjerner et al. Human heterophilic antibodies display specificity for murine IgG subclasses
KR102601835B1 (ko) 말 인플루엔자 바이러스 h3n8형에 특이적인 단일클론항체 및 이를 이용한 말인플루엔자 바이러스 검출용 조성물
TWI741216B (zh) 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途
JP5770092B2 (ja) ヒトｈｉｇ１ポリペプチドに対するモノクローナル抗体
TW202216758A (zh) 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組
WO2020264410A1 (en) Troponin t binding agents and uses thereof
CN114853887B (zh) 一种特异性结合α-突触核蛋白的抗体及其应用
US20210278403A1 (en) Lateral flow assay for assessing recombinant protein expression or reporter gene expression
JP7366411B2 (ja) ヒトαディフェンシンＨＤ５を検出する方法及びキット、並びにこれらにおいて用いられる抗体
EP4194054A1 (en) Camelid antibodies for use in therapy and diagnosis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150202